Foghorn Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

FHTX$1.90-6.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
Collaboration revenue	$6,888	$5,599	$11,938	$10,908
Operating expenses:
Research and development	23,797	29,248	49,331	59,233
General and administrative	7,325	8,401	15,035	17,042
Impairment of long-lived assets	2,398	—	2,398	—
Total operating expenses	33,520	37,649	66,764	76,275
Loss from operations	(26,632)	(32,050)	(54,826)	(65,367)
Other income, net:
Interest income	2,870	2,793	5,309	5,462
Other income, net	783	712	1,522	1,432
Total other income, net	3,653	3,505	6,831	6,894
Loss before income taxes	(22,979)	(28,545)	(47,995)	(58,473)
Provision for income taxes	—	(942)	—	(1,502)
Net loss	$(22,979)	$(29,487)	$(47,995)	$(59,975)
Net loss per share attributable to common stockholders—basic and diluted	$(0.45)	$(0.70)	$(1.02)	$(1.43)
Weighted average common shares outstanding—basic and diluted	51,580,310	41,825,555	47,004,561	41,818,361
Comprehensive loss:
Net loss	$(22,979)	$(29,487)	$(47,995)	$(59,975)
Other comprehensive gain:
Unrealized gains on marketable securities	159	151	488	1,267
Total other comprehensive gain	159	151	488	1,267
Total comprehensive loss	$(22,820)	$(29,336)	$(47,507)	$(58,708)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.